UPDATED: Intercept shares tank as investigators question OCA’s safety/efficacy for NASH

John Carroll After crunching the data on Intercept's clinical study of OCA for nonalcoholic steatohepatitis, investigators say they tracked some distinct improvements for patients ...

WSJ: Salix inventory issues helped scuttle Allergan buyout

Carly Helfand At one time, Allergan was so confident it could lock up an acquisition of Salix Pharmaceuticals to thwart Valeant's hostile bid that it reportedly snubbed potential ...

Ackman, confident Valeant can outbid Actavis, suggests an Allergan auction

Carly Helfand Now that Allergan has two interested buyers on its trail between Valeant and Actavis, leading shareholder and Valeant partner Bill Ackman has an idea: Run an auction. FiercePharma ...

Avanir’s odds for a timely drug approval aren’t looking so good

Damian Garde Avanir Pharmaceuticals, awaiting FDA approval for a new migraine treatment, got a letter from the agency pointing out flaws in submitted data, a regulatory hiccup that ...

FDA lets Endo, Dr. Reddy’s make Valcyte copies but stays mum on status of Nexium generic

Eric Palmer The FDA says it has approved two companies to make generics of Roche's Valcyte but will not give any clarity on plans for a generic of AstraZeneca's blockbuster ...

INC banks $150M in the latest big CRO IPO

Damian Garde INC Research is the latest among Big Pharma's biggest contractors to pull off an IPO, raising $ 150 million and joining its largest rivals on Wall Street. FierceBiotech ...

Eisai ‘speechless’ after another Fycompa price smack-down from Germany

Carly Helfand Germany's cost-effectiveness gatekeepers have delivered another blow to Eisai over the price of Fycompa. And the verdict, just the drugmaker's latest frustration ...

Trevi wraps up a $26M round to fund its anti-itching drug

Damian Garde New Haven, CT's Trevi Therapeutics banked another $ 11 million in venture cash, bringing its B round to $ 26 million and giving it the cash it needs to complete a ...

Tolero wraps up a $22.4M round to support its cancer contender

Damian Garde Tolero Pharmaceuticals has pocketed a second tranche of its Series B funding round, netting $ 22.4 million in total as it prepares to take its expirimental marrow cancer ...

UPDATED: Perrigo snaps up OTC specialist Omega in deal worth $4.5B

Emily Wasserman Perennial dealmaker Perrigo signed on the dotted line for Belgium's Omega Pharma, elbowing past rival bidders to expand its footprint in the global OTC market. ...

Nexium reprieve lets AstraZeneca spend, spend, spend to prep for 2015 knockdown

Tracy Staton AstraZeneca hiked its 2014 forecast for the second time this year. Sales were up by 5%. Instead of apologizing for a lack of growth, CEO Pascal Soriot could crow about ...

GlaxoSmithKline’s effort to relaunch cancer R&D faces skepticism

John Carroll GlaxoSmithKline made a high-profile decision to exit the cancer drug field in its recent deal with Novartis, but as Reuters reports, a band of specialists inside GSK still ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS